Maria C Jugan, Brandon L Plattner, Alexandra K Ford, Leah Freilich, Zackery Bieberly, Thomas Schermerhorn
{"title":"慢性肠病猫血浆胰高血糖素样肽-2。","authors":"Maria C Jugan, Brandon L Plattner, Alexandra K Ford, Leah Freilich, Zackery Bieberly, Thomas Schermerhorn","doi":"10.1177/1098612X241305923","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>The objective of this study was to compare plasma glucagon-like peptide-2 (GLP-2) concentrations in cats with chronic enteropathies (CE) with those of healthy cats.</p><p><strong>Methods: </strong>Nineteen client-owned cats with a histopathologic diagnosis of either idiopathic chronic enteropathy (CIE) or low-grade lymphoma and six healthy client-owned cats were enrolled in a prospective study between 2 December 2021 and 9 June 2023. Fasted and postprandial plasma GLP-2 concentrations were measured via ELISA in CE cats at the time gastrointestinal biopsies were obtained and before CE treatment. In cats with a histopathologic diagnosis of CIE, plasma GLP-2 concentrations were re-evaluated after 1 month of CE treatment.</p><p><strong>Results: </strong>There was no significant difference in plasma GLP-2 concentrations between healthy cats (0.53 ng/ml) and cats with CE (0.52 ng/ml). GLP-2 concentrations in cats with CIE were not significantly different following 1 month of treatment (0.43 ng/ml) from those at initial presentation (0.44 ng/ml).</p><p><strong>Conclusions and relevance: </strong>GLP-2 can be successfully detected in the plasma of cats with CE. Based on the lack of differences observed between this population of CE cats and healthy cats, GLP-2 cannot be recommended as a biomarker of feline CE using this ELISA method. Further investigation of larger CE cat populations and analytic methods would be needed to determine the overall utility of GLP-2 evaluation in feline CE.</p>","PeriodicalId":15851,"journal":{"name":"Journal of Feline Medicine and Surgery","volume":"27 1","pages":"1098612X241305923"},"PeriodicalIF":1.9000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11755514/pdf/","citationCount":"0","resultStr":"{\"title\":\"Plasma glucagon-like peptide-2 in cats with chronic enteropathies.\",\"authors\":\"Maria C Jugan, Brandon L Plattner, Alexandra K Ford, Leah Freilich, Zackery Bieberly, Thomas Schermerhorn\",\"doi\":\"10.1177/1098612X241305923\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>The objective of this study was to compare plasma glucagon-like peptide-2 (GLP-2) concentrations in cats with chronic enteropathies (CE) with those of healthy cats.</p><p><strong>Methods: </strong>Nineteen client-owned cats with a histopathologic diagnosis of either idiopathic chronic enteropathy (CIE) or low-grade lymphoma and six healthy client-owned cats were enrolled in a prospective study between 2 December 2021 and 9 June 2023. Fasted and postprandial plasma GLP-2 concentrations were measured via ELISA in CE cats at the time gastrointestinal biopsies were obtained and before CE treatment. In cats with a histopathologic diagnosis of CIE, plasma GLP-2 concentrations were re-evaluated after 1 month of CE treatment.</p><p><strong>Results: </strong>There was no significant difference in plasma GLP-2 concentrations between healthy cats (0.53 ng/ml) and cats with CE (0.52 ng/ml). GLP-2 concentrations in cats with CIE were not significantly different following 1 month of treatment (0.43 ng/ml) from those at initial presentation (0.44 ng/ml).</p><p><strong>Conclusions and relevance: </strong>GLP-2 can be successfully detected in the plasma of cats with CE. Based on the lack of differences observed between this population of CE cats and healthy cats, GLP-2 cannot be recommended as a biomarker of feline CE using this ELISA method. Further investigation of larger CE cat populations and analytic methods would be needed to determine the overall utility of GLP-2 evaluation in feline CE.</p>\",\"PeriodicalId\":15851,\"journal\":{\"name\":\"Journal of Feline Medicine and Surgery\",\"volume\":\"27 1\",\"pages\":\"1098612X241305923\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11755514/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Feline Medicine and Surgery\",\"FirstCategoryId\":\"97\",\"ListUrlMain\":\"https://doi.org/10.1177/1098612X241305923\",\"RegionNum\":2,\"RegionCategory\":\"农林科学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"VETERINARY SCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Feline Medicine and Surgery","FirstCategoryId":"97","ListUrlMain":"https://doi.org/10.1177/1098612X241305923","RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"VETERINARY SCIENCES","Score":null,"Total":0}
Plasma glucagon-like peptide-2 in cats with chronic enteropathies.
Objectives: The objective of this study was to compare plasma glucagon-like peptide-2 (GLP-2) concentrations in cats with chronic enteropathies (CE) with those of healthy cats.
Methods: Nineteen client-owned cats with a histopathologic diagnosis of either idiopathic chronic enteropathy (CIE) or low-grade lymphoma and six healthy client-owned cats were enrolled in a prospective study between 2 December 2021 and 9 June 2023. Fasted and postprandial plasma GLP-2 concentrations were measured via ELISA in CE cats at the time gastrointestinal biopsies were obtained and before CE treatment. In cats with a histopathologic diagnosis of CIE, plasma GLP-2 concentrations were re-evaluated after 1 month of CE treatment.
Results: There was no significant difference in plasma GLP-2 concentrations between healthy cats (0.53 ng/ml) and cats with CE (0.52 ng/ml). GLP-2 concentrations in cats with CIE were not significantly different following 1 month of treatment (0.43 ng/ml) from those at initial presentation (0.44 ng/ml).
Conclusions and relevance: GLP-2 can be successfully detected in the plasma of cats with CE. Based on the lack of differences observed between this population of CE cats and healthy cats, GLP-2 cannot be recommended as a biomarker of feline CE using this ELISA method. Further investigation of larger CE cat populations and analytic methods would be needed to determine the overall utility of GLP-2 evaluation in feline CE.
期刊介绍：
JFMS is an international, peer-reviewed journal aimed at both practitioners and researchers with an interest in the clinical veterinary healthcare of domestic cats. The journal is published monthly in two formats: ‘Classic’ editions containing high-quality original papers on all aspects of feline medicine and surgery, including basic research relevant to clinical practice; and dedicated ‘Clinical Practice’ editions primarily containing opinionated review articles providing state-of-the-art information for feline clinicians, along with other relevant articles such as consensus guidelines.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
